A refined procedure for esophageal resection using a full minimally invasive approach

Simon K. Ashiku1*, Ashish R. Patel1, Brandon H. Horton2, Jeffrey Velotta1, Sora Ely1 and Andrew L. Avins2

Abstract

Objective: Newer minimally invasive approaches to esophagectomy have brought substantial benefits to esophageal-cancer patients and continue to improve. We report here our experience with a streamlined procedure as part of a comprehensive perioperative-care program that provides additional advances in the continued evolution of this procedure.

Methods: All patients with primary esophageal cancer referred for resection to the Oakland Medical Center of the Kaiser-Permanente Northern California health plan who underwent this approach between January 2013 and August 2018 were included. Operative and clinical outcome variables were extracted from the electronic medical record, operating-room files, and manual chart review.

Results: 142 patients underwent the new procedure and care program; 121 (85.2%) were men with mean age of 64.5 years. 127 (89.4%) were adenocarcinoma; 117 (82.4%) were clinical stage III or IVA. 115 (81.0%) required no jejunostomy. Median hospital length-of-stay was 3 days and 8 (5.6%) patients required admission to the intensive care unit. Postoperative complications occurred in 22 (15.5%) patients within 30 days of the procedure. There were no inpatient deaths; one patient (0.7%) died within 30 days following discharge and three additional deaths (2.1%) occurred through 90 days of follow-up.

Conclusions: This approach resulted in excellent clinical outcomes, including short hospital stays with limited need for the intensive care unit, few perioperative complications, and relatively few patients requiring feeding tubes on discharge. This comprehensive approach to esophagectomy is feasible and provides another clinically meaningful advance in the progress of minimally invasive esophagectomy. Further development and dissemination of this method is warranted.

Keywords: Esophagectomy, Esophageal cancer, Minimally invasive surgery

Introduction

Esophageal cancer is the seventh most common cancer worldwide and the sixth leading cause of cancer-related death [1], reflecting its generally poor prognosis. In 2018 in the United States, there were over 17,000 incident cases and 15,000 deaths [2]. Overall 5-year survival is approximately 20% [3], and most patients will die within one year of diagnosis [4].

This situation creates a compelling need to minimize treatment-associated morbidity to provide esophageal cancer patients with the maximum quality of life for their often-limited expected survival. However, the primary treatment modality for esophageal cancer, surgical resection, has been associated with high morbidity and mortality. In a review of Medicare data...
between 1997 and 2003, esophagectomies (primarily open procedures) were associated with an inpatient mortality of 3.0% and a 30-day mortality of 14% [5].

In an effort to improve on the outcomes of esophagectomy, Cuschieri, et al. developed and were the first to report on a minimally invasive esophagectomy (MIE) approach in 1992 [6]. The technique was considered experimental until Luketich et al.’s landmark 2003 series of 222 MIE procedures, which were associated with an operative mortality of only 1.4% [7]. Since that time, the procedure has been widely adopted and has progressively evolved as thoracic surgeons continue to incorporate additional innovations into the technique.

Despite the advantages over conventional open resections, there remain important areas for continued improvement in the process and postoperative outcomes associated with MIE procedures. Recent data show that median hospital length of stay (LOS) remains at approximately one week for MIE [8–39]. Median intensive care unit (ICU) length of stay, when reported, is typically between 1 and 3 days for both open and MIE procedures [9, 12, 14, 16, 17, 20, 26, 27, 30–32, 36, 37, 39, 40]. Reported 30-day readmission rates are typically 9–15% [11, 18, 22, 32, 41, 42]. Although minimally invasive surgical approaches to esophagectomy have important advantages, reported complication rates remain in the range of 23–65% [8, 10, 12, 13, 15–17, 19, 21–29, 29, 32, 33, 35, 36, 38–40, 42–46]. Furthermore, transabdominal jejunostomy feeding tubes are generally placed for post-operative nutrition, potentially causing postoperative complications [47] and delaying return-to-baseline functional status; routine feeding tube placement is described in most protocols and in three large series, ≥84% of patients were discharged home with feeding tubes [20, 37, 40]. Hence, there continue to be opportunities for further development and enhancement of the MIE approach. In addition, substantial advances have been made in perioperative care, such as enhanced-recovery-after-surgery (ERAS) protocols, providing potential additional improvements in patients’ overall surgical experience.

Building on the notable progress made by prior surgical innovators, we sought to improve preoperative, intraoperative, and postoperative aspects of MIE, with the goal of improving esophageal cancer patients’ morbidity, mortality, and return-to-baseline functional status. We report here our experience with a streamlined fully minimally invasive operative approach along with a comprehensive perioperative care program.

Methods
Study design
We conducted a retrospective review of consecutive cases of Kaiser Permanente Northern California (KPNC) patients who underwent this streamlined MIE procedure and perioperative-care program (described below) and detailed in the accompanying document (Additional file 1). KPNC is an integrated health plan serving 4.4 million members through a network of 21 medical centers in Northern California. The demographics of KPNC approximate the underlying demographics of the geographic region [48]. All study procedures were approved by the KPNC Institutional Review Board.

Subjects
Eligible patients were KPNC members referred for esophagectomy who underwent this MIE procedure at the KPNC Oakland Medical Center by one of five board-certified attending thoracic surgeons between January 2013 and August 2018; additional eligibility criteria included a surgical indication of primary esophageal cancer, a requirement that the procedure was elective, that the surgery consisted of the MIE only (i.e., not combined with another procedure during the same surgery), and that the patient had 90 days of postoperative follow-up at the time of data analysis (patients who died within 90 days of surgery were not excluded). All patients meeting these eligibility criteria were included and full ascertainment of all relevant patients was achieved by a search of the electronic medical record (EMR), operating-room records, and a list maintained by the first author. All patients who underwent the procedure in the specified interval were included in the final cohort, including those with extremely advanced disease for whom surgery was performed at the patient’s request and were not expected to survive. Postoperative follow-up for surgical outcomes (including complications and mortality) was carried out for 90 days postoperatively on all patients; mortality follow-up was carried out to a maximum of 84.0 months (median: 29.0 months; survival curves were truncated when fewer than 10 patients remained at risk); data on mortality were obtained from the EMR and state and federal mortality databases.

Description of perioperative and operative procedures
Perioperative care was guided by strict adherence to ERAS protocols, which included patient education with preoperative nutritionist consultation, mandatory perioperative medicine clinic consultation, carbohydrate loading with clear liquids 2-to-4 h preoperatively, avoidance of perioperative use of sedating medications, and use of
nonopioid multimodal analgesia. Postoperatively, the urinary catheter and nasogastric tube were removed on the first day and a clear-liquid diet started and early ambulation instituted. Detailed descriptions of all aspects of the KPNC ERAS protocols are provided elsewhere [49, 50]. Most patients are discharged on postoperative day 3 (patients are eligible for discharge on day 3 if they have no leak on the esophagram, absence of tachycardia or fever, are able to sustain hydration and nutrition with over 2 L of fluid orally per day, their pain is adequately treated with oral medication, and they appear clinically well). Patients call or text the surgeon daily for 10 days after discharge after which they are seen in clinic; physician assistants assist in monitoring discharged patients.

The procedure described in this paper is classified as “IVL-LV” in the taxonomy of a recent consensus statement [51]. Briefly, the MIE in this study was performed in the following manner: The abdominal portion was conducted through a 15 mm, 10 mm, three mm ports and a 5 Nathanson liver retractor. The camera was operated by a surgical trainee. Both surgeon and assist employed two instruments. The hiatus was mobilized and Penrose drain placed, the greater curvature mobilized, the left gastric divided with a stapler and the stomach partially tubularized with three thick tissue stapler loads. Jejunostomy tube placement, the pyloroplasty, and the Kocherization of the duodenum were not done. To avoid trauma to the gastric conduit it was never grasped by instruments. The thoracic portion was conducted through four 10 mm ports and a 40–50 mm utility port. The pleura was incised caudal to cephalad and mobilized off the spine. The Penrose was retrieved at the hiatus and the esophagus and periesophageal tissue mobilized. A longitudinal incision was made in the upper esophagus to allow insertion of the anvil, the esophagus transected, and the anvil secured with two endoloop sutures. A gastrostomy was made on the lesser curvature and the stapler inserted. An anastomosis was created as proximal as possible and the tubularization complete leaving a 2 cm bridge. The pleura was closed with interrupted 2.0 silk sutures cranial to caudal.

Variables
Patient-related data included demographics and clinical comorbidities (i.e., specific comorbidities and the Charlson-Quan Comorbidity Index summary score [52]), American Society of Anesthesiologists (ASA) preoperative risk score (range 1–5) [53], Eastern Cooperative Oncology Group (ECOG) performance-status score (range 0–5) [54], and neoadjuvant therapy received. Tumor-related variables included cell type, primary esophageal site, clinical and pathologic stage (consistent with the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) staging system, 8th edition, 2017 [55]) and regional lymph-node status. Variables related to the surgical procedure included both full operating-room time and “skin-to-skin” time (time between first incision and final closure), estimated blood loss, jejunostomy status, pleural-closure status and whether an intra-pyloric botulinum injection was used. Outcome variables included LOS for the overall hospitalization and for the ICU specifically as well as 30-day incidence of hospital readmission, emergency-department visits, whether the patient was discharged with a feeding tube in place, reoperation, and all-cause and cancer-specific mortality. Perioperative complications and post-discharge complications were all reviewed by the first author (SA) and categorized by the U.S. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) system, v5.0 [56].

Data sources
Data for this study were obtained by extraction of relevant variables from the EMR database supplemented by manual chart review for those variables not available in discrete electronic form. Some cancer-related variables were obtained from a KPNC Cancer Registry maintained by the KPNC Division of Research for research purposes and for reporting to the Surveillance, Epidemiology, and End Results (SEER) program of the U.S. National Cancer Institute [57]. Data domains extracted from the EMR included demographics, clinical comorbidities, overall hospital ICU length of stay, readmission rates, and mortality. Variables requiring manual chart review included clinical and pathologic staging, lymph-node involvement, specific procedure-related variables, operative times from anesthesia records, and procedure-related complications. Manual chart data extraction was conducted by SA, AA, and BH.

Data analysis
Continuous variables were summarized as means with Wald 95% confidence intervals and/or medians with the associated interquartile ranges (IQRs). Categorical variables were summarized with percentages and 95% confidence intervals (95% CI) were calculated with the exact Clopper-Pearson method [58]. Survival data for both total and cancer-specific mortality were summarized with Kaplan–Meier failure-time plots [59]. Comparisons of surgeries between the first and second halves of the cohort were conducted with nonparametric Wilcoxon rank-sum tests for continuous variables and Fisher’s exact tests for categorical variables.
**Results**

**Patients**

One hundred fifty-two KPNC patients underwent this MIE procedure-and-care program between January 2013 and August 2018; of these, 10 patients were excluded for the following reasons: seven cases were complex procedures in which the MIE was combined with a second procedure during the same surgery (e.g., adrenalectomy, colon transposition, or lung lobectomy), two were unplanned salvage procedures, and one case was performed for recurrent esophageal cancer. The final analytic cohort was comprised of the remaining 142 patients (Table 1). No patient had a planned elective esophagectomy at this medical facility by any other procedure (e.g., open esophagectomy). All patients underwent the procedure for esophageal cancer, nearly all of whom had disease in the lower third of the esophagus or at the gastroesophageal junction (90.8%) and had adenocarcinoma histology (89.4%). Eighty-five cancers (59.9%) were clinical stage III and 32 (22.5%) were clinical stage IVA. The mean age of all patients was 64.5 years and the majority (85.2%) were men. One hundred twenty-five (88.0%) received some form of neoadjuvant therapy.

**Operative outcomes**

Of the 142 procedures, 1 required conversion to an open laparotomy due to intraoperative technical difficulties. The median total patient operating room time was 290 min (IQR: 255 to 348 min; mean: 306.5 min) and the median “skin-to-skin” time was 237 min (IQR: 210 to 290 min; mean: 254.6 min) (Table 2). One hundred fifteen patients (81.0%, 95% CI: 73.6% to 87.0%) did not have a jejunostomy placed during or after surgery.

**Clinical outcomes**

The median hospital LOS was 3 days (IQR: 2 to 4 days); the mean was 3.6 days (95% CI: 3.1 to 4.0 days). Only 8 patients (5.6%, 95% CI: 2.5% to 10.8%) required postoperative care in the ICU (all were unplanned) and, of these, only 1 patient required care for more than 4 days (Table 3). Twenty-two patients (15.5%, 95% CI: 10.0% to 22.5%) suffered a total of 25 complications within 30 days following the surgical procedure (Table 3); 14 patients (9.9%) experienced a complication with a CTCAE severity score of ≥3. The most common complications were pneumonia, atrial fibrillation, and anastomotic leaks (the frequencies of all complications are detailed in Table 3). In addition to these complications, 21 patients (14.8%) had a postoperative anastomotic

---

**Table 1** Demographic and clinical characteristics of patients undergoing minimally invasive esophagectomy (N = 142)

| Characteristic                                      | Value                  |
|----------------------------------------------------|------------------------|
| **Demographics**                                    |                        |
| Age at time of surgery [years]                      | Mean (SD) 64.5 (9.6)   |
|                                                   | Median (IQR) 66.5 (59–70) |
| Male gender [N (%)]                                | 121 (85.2%)            |
| BMI [kg/m²]                                        | Mean (SD) 27.4 (5.4)   |
| Race [N (%)]                                        |                        |
| African-American                                   | 7 (4.9%)               |
| Asian                                              | 12 (8.5%)              |
| Native American                                    | 1 (0.7%)               |
| White                                              | 122 (85.9%)            |
| Hispanic                                            | 10 (7.0%)              |
| **Clinical characteristics**                        |                        |
| Primary site [N (%)]                               |                        |
| Mid-thoracic esophagus                              | 13 (9.2%)              |
| Lower thoracic esophagus                            | 76 (53.5%)             |
| Gastroesophageal junction                           | 53 (37.3%)             |
| Histology [N (%)]                                   |                        |
| Adenocarcinoma                                      | 127 (89.4%)            |
| Squamous cell carcinoma                             | 11 (7.8%)              |
| Other                                               | 4 (2.8%)               |
| **Clinical stage [N (%)]                            |                        |
| Stage 0                                             | 2 (1.4%)               |
| Stage I                                             | 10 (7.0%)              |
| Stage IIa                                           | 4 (2.8%)               |
| Stage IIb                                          | 9 (6.3%)               |
| Stage III                                          | 85 (59.9%)             |
| Stage IVA                                           | 32 (22.5%)             |
| Stage IVB                                          | 0 (0%)                 |
| **Pathologic stage [N (%)]                          |                        |
| Stage 0                                             | 28 (19.7%)             |
| Stage I                                             | 22 (15.5%)             |
| Stage IIa                                           | 7 (4.9%)               |
| Stage IIb                                          | 17 (12.0%)             |
| Stage III                                          | 39 (27.5%)             |
| Stage IVA                                           | 28 (19.7%)             |
| Stage IVB                                          | 1 (0.7%)               |
| **Regional lymph nodes involved (Clinical staging) [N (%)]** | 87 (61.3%) |
| **Regional lymph nodes involved (Pathologic staging) [N (%)]** | 53 (37.3%) |
| **ECOG performance status [N (%)]**                 |                        |
| 0                                                   | 42 (29.6%)             |
| 1                                                   | 48 (33.8%)             |
| 2                                                   | 12 (8.5%)              |
| Unknown                                             | 40 (28.2%)             |
| **Neoadjuvant therapy [N (%)]**                     |                        |
| Radiation therapy only                              | 1 (0.7%)               |
| Chemotherapy only                                   | 15 (10.6%)             |
| Chemoradiation                                      | 109 (76.8%)            |
Within the 30 days after discharge, 14 patients (9.9%, 95% CI: 5.5% to 16.0%) were readmitted to the hospital. Thirty-six patients (25.4%, 95% CI: 18.4% to 33.3%) were evaluated in the emergency department, and 6 patients (4.2%, 95% CI: 1.6% to 9.0%) were taken back to the operating room (three for anastomotic leak, one for gastric conduit loss, one for empyema, and one for tracheostomy and jejunostomy to treat respiratory failure). No patient died intraoperatively or prior to discharge (0%, 95% CI: 0% to 2.6%); 1 patient (0.7%, 95% CI: 0.02% to 3.9%) died within 30 days post-procedure; 3 additional patients died between 31 and 90 days post-operatively (full 90-day mortality: 2.8%, 95% CI: 0.8% to 7.1%). The Kaplan–Meier product-limit estimate of the longer-term total mortality experience of this cohort is shown in Fig. 1 (total median survival was 4.6 years); cancer-specific survival is shown in Fig. 2.

Comparing surgeries performed in the earlier half of the cohort (prior to January 20, 2016) to the latter half, we found a reduction in the median hospital length of stay (4 days vs. 2 days, \( p < 0.001 \)), median skin-to-skin procedure time (259 min vs. 229 min, \( p = 0.01 \)), median number of lymph nodes excised (18 nodes vs. 14 nodes, \( p = 0.002 \)), and risk of readmission within 30 days of discharge (11 (15.5%) vs. 3 (4.2%), \( p = 0.046 \)).

**Table 1** (continued)

| Characteristic                  | None | 17 (12.0%) |
|---------------------------------|------|------------|
| Preoperative ASA Category [N (%)] |      |            |
| 1                               | 0 (0%) |            |
| 2                               | 50 (35.2%) |        |
| 3                               | 91 (64.1%) |        |
| 4                               | 1 (0.7%) |            |
| 5                               | 0 (0%) |            |
| **Clinical comorbidities [N (%)]** |      |            |
| Hypertension                    | 87 (61.3%) |        |
| Diabetes                        | 47 (33.1%) |        |
| Coronary artery disease         | 43 (30.3%) |        |
| Heart failure                   | 8 (5.6%) |            |
| Chronic renal insufficiency     | 26 (18.3%) |        |
| Chronic obstructive pulmonary disease | 13 (9.2%) |        |
| Stroke/Transient ischemic attack | 4 (2.8%) |            |
| Charlson-Quan Comorbidity Index | Mean (SD) 6.0 (5.6–6.4) | |
| Median (IQR)                    | 7 (4–8) |            |

ASA American Society of Anesthesiologists, BMI Body Mass Index, ECOG Eastern Cooperative Oncology Group, IQR Interquartile range, SD standard deviation

---

Esophageal cancer is a deadly disease, with an overall 5-year survival of only 19% [4] and esophagectomy remains the mainstay of treatment. Since the introduction of the minimally invasive approach to esophagectomy in 1992 [6], there have been important improvements in the technique and outcomes associated with the procedure, though many patients continue to be burdened by surgical morbidity, lifestyle restrictions (e.g., use of feeding tubes), and prolonged hospitalization. Accordingly, thoracic surgeons have continued to build on prior innovations to further improve on the promise of MIE [60].

In this paper, we describe the process and clinical outcomes associated with a streamlined surgical approach to MIE developed at our institution among 142 consecutive patients with esophageal cancer treated with this procedure. This surgical technique was built around a fully minimally invasive approach incorporating updated techniques used by our group and others, motivated by prior advances in the procedure. In addition, we were careful
to adhere to the principles of ERAS [49] with careful patient preparation and close post-discharge outpatient follow-up, further optimizing both the surgical and perioperative experience. No patient was lost to follow-up for the assessment of 90-day postoperative outcomes.

In conjunction with well-coordinated preoperative and postoperative care, we found this approach was associated with excellent outcomes, substantially improving objective measures of surgical and perioperative performance as well as the patient experience. In particular, we found that this comprehensive perioperative and surgical approach was associated with relatively shorter operative times, decreased need for both intensive-care and overall inpatient hospitalization, reduced need for feeding tubes, and acceptable adverse-event, reoperation, and readmission rates.

For example, we observed a median inpatient LOS of 3 days in our series with no patient requiring a routine ICU admission and only 5.6% requiring a subsequent transfer to the ICU for management of complications. These results compare favorably with prior published MIE studies with reported hospital LOS's between 7 and 33 days [8–40]; most studies reported LOS’s of at least 12 days, with the largest case series reporting LOS’s of 8 to 15 days [18, 20, 22, 32, 35]. The great majority of studies that provided data on intensive care unit LOS's reported a median of at least one day [9, 12, 14, 16, 17, 20, 26, 27, 30–32, 36, 37, 39, 40, 61]. Furthermore, the elimination of a routine ICU admission and shorter overall LOS did not adversely affect rates of readmission or reoperation: our readmission rate was 12%, similar to previously reported rates of 9–18% [11, 18, 22, 32, 41, 42]. In addition, only 19% (95% CI: 12.9% to 26.4%) of our patients required placement of a jejunostomy tube, compared with reported rates of 84% [37], 95% [20], and 97% [40], among many other series that described routine jejunostomy-tube placement as part of the surgical protocol. We also found continued improvements comparing the earlier half of cohort with the latter half, suggesting that the learning curve for performing this procedure continued throughout the study period.

Comparing surgical complications across series is admittedly difficult since there is great variability in reporting standards. However, with respect to individual complications, we observed anastomotic leaks in 3 patients (2.1%, 95% CI: 0.4–6.0%) compared with others’ reported rates that ranged from 0 to 21% [8, 10–12, 14, 16, 17, 19, 21, 23–40, 42–44, 61–63] with a median rate of 10% and a range from 5.5 to 21% among the five largest series that reported relevant rates [32, 35, 36, 42, 63]. In our series, pulmonary complications occurred in 14 patients (9.9%; 95% CI: 5.5% to 16.0%), including 9 cases (6.3%) of pneumonia and 2 cases (1.4%) of empyema; there were no cases of adult respiratory distress syndrome (ARDS) or chylothorax. These results compare favorably with rates from other centers with reported postoperative pneumonia rates ranging from 2 to 20% [10, 13–16, 19, 22, 25, 28, 29, 35–38, 40, 43, 44] with the median reported rate of 8%, and reported rates

### Table 3  Patient clinical outcomes (N = 142)

| Clinical outcomes                                      | N (%)       |
|--------------------------------------------------------|-------------|
| Hospital length of stay [days]                         |             |
| Mean (SD)                                              | 3.6 (3.0)   |
| Median (IQR)                                           | 3 (2–4)     |
| Intensive care length of stay (N %)                    |             |
| No intensive care days                                 | 134 (94.4%) |
| 1–2 days                                               | 4 (2.8%)    |
| 3–4 days                                               | 3 (2.1%)    |
| ≥ 5 days                                               | 1 (0.7%)    |
| Readmission within 30 days [N %]                       | 14 (9.9%)   |
| Post-discharge emergency department visit within 30 days [N %] | 36 (25.4%) |
| Return to operating room within 30 days [N %]          | 6 (4.2%)    |
| Required post-operative balloon pyloroplasty [N %]     | 33 (23.2%)  |
| Mortality [N %]                                        |             |
| In-hospital                                            | 0 (0%)      |
| Within 30 days of discharge                            | 1 (0.7%)    |
| 31–90 days after discharge                             | 3 (2.1%)    |
| Patients with ≥ 1 complication within 30 days of surgery [N %] | 22 (15.5%) |
| Highest CTCAE complication grade                       | 0 (0%)      |
| Grade 1                                                | 8 (5.6%)    |
| Grade 2                                                | 8 (5.6%)    |
| Grade 4                                                | 4 (2.8%)    |
| Grade 5 (death)                                        | 2 (1.4%)    |
| Specific Complications                                 |             |
| Atrial fibrillation                                    | 4 (2.8%)    |
| Anastomotic leak                                       | 3 (2.1%)    |
| Dehydration                                            | 1 (0.7%)    |
| Empyema                                                | 2 (1.4%)    |
| Gastric conduit necrosis                               | 1 (0.7%)    |
| Myocardial infarction                                  | 1 (0.7%)    |
| Pleural effusion                                       | 1 (0.7%)    |
| Pneumonia                                              | 9 (6.3%)    |
| Pneumothorax                                           | 1 (0.7%)    |
| Respiratory failure                                    | 1 (0.7%)    |
| Urinary tract infection (cystitis)                     | 1 (0.7%)    |

CTCAE common terminology criteria for adverse events, IQR interquartile range, SD standard deviation
of empyema ranging from 0 to 4.1% [15, 20, 35, 37, 39, 42] with a median rate of 3.8%. Rates of ARDS reported in prior series range from 1 to 8% [8, 10, 16, 20, 23, 35, 40, 43] with a median of 3.3%; reported rates of chylothorax range from 1 to 11% [12, 14, 15, 17, 19, 23, 24, 26, 31, 32, 35, 37–40, 42, 44, 62] with the median reported rate of 3%. No patient died during the index hospitalization and 30-day mortality was 0.7% (95% CI: 0.02% to 3.9%) compared with reported rates in other series of 0–11% [9, 11, 12, 16, 18–20, 22–24, 32, 34–37, 40, 43, 45, 61, 63] (with most in the range of 2–4%).

The reasons for the favorable outcomes we observed were likely multifactorial. While the fundamental surgical principles remained unchanged for the esophagectomy itself, we streamlined several technical aspects, eliminating the need for the pyloroplasty, jejunostomy and Kocherization. Meticulous attention was made to avoid tissue trauma to the gastric conduit by utilizing a “no-grab” technique, implementing partial conduit tubularization, and avoiding a linear gastrotomy. Having two subspecialty thoracic surgeons working together further reduced time under anesthesia.

The decrease in hospital LOS reflects not only improved intraoperative techniques, but also intensive perioperative management. Saving the right pleura and reconstituting the mediastinal envelope eliminated the need for a feeding tube and allowed early removal of the nasogastric tube with resultant initiation of oral nutrition on the first postoperative day. Of particular note, only 19% of our patients required placement of a feeding jejunostomy tube compared to much higher rates reported in the literature. Employing a closed suction drain provided continued chest drainage, which could be continued as an outpatient to monitor for leaks. Postoperative pain management was simplified by administering long-acting intercostal nerve blocks thereby eliminating epidural catheters. Early alimentation and ambulation allowed the patient to recover earlier at home. There was daily telephone communication with a staff surgeon and on-demand access as necessary to monitor patients’ progress and address any patient concerns. Return visits were mostly limited to drain removal. The combination of a streamlined procedure, strict adherence to ERAS protocols by a highly coordinated perioperative team, and close postoperative follow-up all likely contributed to the favorable patient outcome and experience.

Our case series has several strengths, including a consecutive closed cohort, complete 90-day follow-up, and detailed clinical and utilization EMR data. Our patient sample was typical of patients in other cohorts and trials in terms of age, gender, ASA classification, cancer stage, comorbidities, and use of neoadjuvant therapy. However, several limitations of this report should be noted. First, this study was based on a single-center, retrospective design. Additionally, this was a study of a streamlined surgical approach along with instituting a centralized multidisciplinary care method; therefore, it was not possible to determine the impact of each individual component on the improved outcomes. Although several surgeons performed the new procedure, suggesting the results are not limited to the practice of a single practitioner, generalizability will need to be validated in other practice settings. Finally, the retrospective data collection did not allow for assessment of standardized quality-of-life assessments.
Conclusions
We found that an enhanced method of performing esophagectomy, employing a full minimally invasive approach, combined with a well-developed multidisciplinary perioperative-care program resulted in important improvements and excellent outcomes for the initial surgical treatment of esophageal cancer among the patients in our series. Further research should examine the generalizability of this approach and continue its development (ideally employing comparative clinical trials) to further improve the clinical experience and outlook for patients with esophageal cancer eligible for surgical resection.

Abbreviations
AJCC: American Joint Committee on Cancer; ARDS: Adult respiratory distress syndrome; ASA: American Society of Anesthesiologists; CTCAE: Common Terminology Criteria for Adverse Events; ECOG: Eastern Cooperative Oncology Group; EMR: Electronic medical record; ERAS: Enhanced recovery after surgery; ICU: Intensive care unit; KPNC: Kaiser Permanente, Northern California; LOS: Length of stay; MIE: Minimally invasive esophagectomy; SEER: Surveillance, Epidemiology, and End Results; UICC: Union for International Cancer Control.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13019-022-01765-2.

Additional file 1: Details of the operative and perioperative procedures for the minimally invasive esophagectomy procedure described in the text.

Acknowledgements
Not applicable.

Authors’ contributions
SKA: Conceived the study, conducted manual chart review for variables not available in discrete form in the electronic medical record, participated in writing the first draft of the manuscript, participated in the manuscript review and revisions. ARP: Participated in reviewing the data and in the manuscript review. SKA: Conducted manual chart review for variables not available in discrete form in the electronic medical record, conducted manual chart review for additional variables, participated in conducting the statistical analysis, participated in the manuscript review and revisions. JV: Participated in reviewing the data and in the manuscript review and revisions. SE: Participated in reviewing the data and in the manuscript review and revisions. ALA: Conducted manual chart review for variables not available in discrete form in the electronic medical record, participated in conducting the statistical analysis, participated in writing the first draft of the manuscript, participated in the manuscript review and revisions. All authors read and approved the final manuscript.

Funding
This project was supported by The Permanente Medical Group's Delivery Science and Applied Research program.

Availability of data and materials
The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
This study was conducted under full-committee approval from the KPNC Institutional Review Board (Approval Number: 1279152 (April 30, 2017)). As a data-only, secondary analysis of existing data, the requirement for individual consent by study subjects was waived by the IRB.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Thoracic Surgery, Northern California Kaiser-Permanente, 3600 Broadway, Oakland, CA 94611, USA. 2Division of Research, Northern California Kaiser-Permanente, Oakland, CA, USA.

Received: 13 May 2021   Accepted: 2 February 2022
Published online: 04 March 2022

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
3. Esophageal Cancer—Cancer Stat Facts. SEER [cited 2019 Apr 11]. https://seer.cancer.gov/statfacts/html/esoph.html.
4. Njei B, McCarty TR, Birk JW. Trends in esophageal cancer survival in United States adults from 1973 to 2009: a SEER database analysis. J Gastroenterol Hepatol. 2016;31(6):1141–6.
5. Ra J, Paulson EC, Kucharczuk J, Armstrong K, Wirtalla C, Rapaport-Kelz R, et al. Postoperative mortality after esophagectomy for cancer: development of a preoperative risk prediction model. Ann Surg Oncol. 2008;15(6):1577–84.
6. Cuschieri A, Shimi S, Banting S. Endoscopic oesophagectomy through a right thoracoscopic approach. J R Coll Surg Edinb. 1992;37(1):7–11.
7. Luketich JD, Alvelo-Rivera M, Buenaventura PO, Christie NA, McCaughan JS, Litle VR, et al. Minimally invasive oesophagectomy: outcomes in 222 patients. Ann Surg. 2003;238(4):486–94 (discussion 494–495).
8. Berger AC, Bloomenthal A, Wekler B, Evans N, Chojnacki KA, Yeo CJ, et al. Oncologic efficacy is not compromised, and may be improved with minimally invasive esophagectomy. J Am Coll Surg. 2011;212(4):560–6 (discussion 566–568).
9. Bierie SSAY, van Berge Henegouwen MI, Maas KW, Bonavina L, Rosman C, Garcia JP, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet Lond Engl. 2012;379(9829):1887–92.
10. Briez N, Piessen G, Torres F, Lebuffe G, Triboulet J-P, Mariette C. Effects of hybrid minimally invasive oesophagectomy on major postoperative pulmonary complications. Br J Surg. 2012;99(11):1547–53.
11. Findlay L, Yao C, Bennett DH, Byrom R, Davies N. Non-inferiority of minimally invasive oesophagectomy: an 8-year retrospective case series. Surg Endosc. 2017;31(9):3681–9.
12. Gao Y, Wang Y, Chen L, Zhao Y. Comparison of open three-field and minimally-invasive esophagectomy for esophageal cancer. Interact Cardiovasc Thorac Surg. 2011;12(3):366–9.
13. Glatz T, Marjanovic G, Kulemann B, Sick O, Hopt UT, Hoeppner J. Hybrid minimally invasive esophagectomy vs. open esophagectomy: a matched case analysis in 120 patients. Langenbecks Arch Surg. 2017;402(2):323–31.
14. Javadfar J, Bacchetta M, Yang JA, Miller J, D’Ovidio F, Ginsburg ME, et al. The use of a tailored surgical technique for minimally invasive esophagectomy. J Thorac Cardiovasc Surg. 2012;143(5):1125–9.
15. Kauppi J, Räisänen J, Silho E, Huhtanen R, Niskälä K, Salo J. Open versus minimally invasive esophagectomy: clinical outcomes for locally advanced esophageal adenocarcinoma. Surg Endosc. 2015;29(9):2614–9.
16. Kinjo Y, Kurita N, Nakamura F, Okabe H, Tanaka E, Kataoka Y, et al. Effectiveness of combined thoracoscopic-laparoscopic esophagectomy: comparison of postoperative complications and midterm oncological outcomes in patients with esophageal cancer. Surg Endosc. 2012;26(2):381–90.
17. Kubo N, Ohira M, Yamashita Y, Sakurai K, Toyokawa T, Tanaka H, et al. The impact of combined thorascopic and laparoscopic surgery on pulmonary complications after radical esophagectomy in patients with resectable esophageal cancer. Anticancer Res. 2014;34(5):2399–404.

18. Lazzarino AI, Nagpal K, Bottle A, Faiz O, Moorthy K, Aylin P. Open versus minimally invasive esophagectomy: trends of utilization and associated outcomes in England. Ann Surg. 2010;252(2):292–8.

19. Li J, Shen Y, Tan L, Feng M, Wang H, Xi Y, et al. Is minimally invasive esophagectomy beneficial to elderly patients with esophageal cancer? Surg Endosc. 2015;29(4):925–30.

20. Luketich JD, Pennathur A, Aways O, Levy RM, Keesley S, Shende M, et al. Outcomes after minimally invasive esophagectomy: review of over 1000 patients. Ann Surg. 2012;256(1):95–103.

21. Maas KW, Biere SSAY, Scheepers JJG, Gisbertz SS, van-der-Peet DL, Cuesta A. Laparoscopic versus open transhiatal esophagectomy for distal and junction cancer: Rev Espana Enfermedad Dig Ogan Soc Espaola Patol Dig. 2012;104(4):197–202.

22. Mamidanna R, Bottle A, Aylin P, Faiz O, Hanna GB. Short-term outcomes following open versus minimally invasive esophagectomy for cancer in England: a population-based national study. Ann Surg. 2012;255(2):197–203.

23. Mariette C, Markar SR, Dabakuyo-Yonli TS, Meunier B, Pezet D, Collet D, et al. Hybrid minimally invasive esophagectomy for esophageal cancer: N Engl J Med. 2008;358(2):152–62.

24. Meng F, Li Y, Ma H, Yan M, Zhang R. Comparison of outcomes of open and minimally invasive esophagectomy in 183 patients with cancer. J Thorac Dis. 2014;6(9):1218–24.

25. Naffouje SA, Salloum RH, Khalaf Z, Saiﬁ GL. Outcomes of open versus minimally invasive Ivor-Lewis esophagectomy for cancer: a propensity-score matched analysis of NSQIP database. Ann Surg Oncol. 2019;26(7):2001–10.

26. Noble F, Kelly JJ, Bailey IS, Byrne JP, Underwood TJ, South Coast Cancer Collaboration - Oesophago-Gastric (SC3-OG). A prospective comparison of totally minimally invasive versus open Ivor Lewis esophagectomy. Dis Esophagus Off J Int Soc Dis Esophagus. 2013;26(3):263–71.

27. Paireder M, Asari R, Kristo I, Rieder E, Zacherl J, Kabon B, et al. Morbidity in open versus minimally invasive hybrid esophagectomy (MIOHBE): long-term results of a randomized controlled clinical study. Eur Surg Acta Chir Austriaca. 2018;50(6):249–55.

28. Palazzo F, Rosato EL, Chaudhary A, Evans NR, Sendecki JA, Keith S, et al. Minimally invasive esophagectomy for cancer in England: a population-based national study. Ann Surg Oncol. 2011;18(5):1455–63.

29. Parameswaran R, Veeramootoo D, Krishnadas R, Cooper M, Berrisford R, Wajed S. Comparative experience of open and minimally invasive esophago-gastric resection. World J Surg. 2003;30(3):1868–75.

30. Rodham P, Batty JA, McElroy P, Immanuel A. Does minimally invasive esophagectomy provide a benefit in hospital length of stay when compared with open oesophagectomy? Interact Cardiovasc Thorac Surg. 2016;22(3):360–7.

31. Safiinem PK, Cubitt J, Booth MJ, Dehn TCB. Review of open and minimally invasive approaches to oesophagectomy for cancer. Br J Surg. 2010;97(12):1845–53.

32. Seessing MJ, Gibertetz SS, Goense L, van Hillegebergren K, Kroon HM, Lagarde SM, et al. A propensity score matched analysis of open versus minimally transthoracic esophagectomy in the Netherlands. Ann Surg. 2017;266(5):839–46.

33. Shen Y, Zhang Y, Tan L, Feng M, Wang H, Khan MA, et al. Extensive mediastinal lymphadenectomy during minimally invasive esophagectomy: optimal results from a single center. J Gastrointest Surg Off J Soc Surg. 2010;14(5):715–21.

34. Shiraiishi T, Kawaihara K, Shirakusa T, Yamamoto S, Maekawa T. Risk analysis in resection of thoracic esophageal cancer in the era of endoscopic surgery. Ann Thorac Surg. 2006;81(3):1083–9.

35. Sihag S, Kosinski AS, Gaisser HA, Wright CD, Schipper PH. Minimally invasive versus open esophagectomy for esophageal cancer: a comparison of early surgical outcomes from the society of thoracic surgeons national database. Ann Thorac Surg. 2016;101(4):1281–8.

36. Smithers BM, Gotlieb DC, Martin I, Thomas JM. Comparison of the outcomes between open and minimally invasive esophagectomy. Ann Surg. 2007;245(2):232–40.

37. Tapias LF, Mathiesen DJ, Wright CD, Wain JC, Gaisser HA, Muniappan A, et al. Outcomes with open and minimally invasive Ivor Lewis esophagectomy after neoadjuvant therapy. Ann Thorac Surg. 2016;101(3):1097–103.

38. Yamazaki M, Miyata H, Fujiwara Y, Takiguchi S, Nakajima K, Kurakawa Y, et al. Minimally invasive esophagectomy for esophageal cancer: comparative analysis of open and hand-assisted laparoscopic abdominal lymphadenectomy with gastric conduit reconstruction. J Surg Oncol. 2011;104(6):623–8.

39. Zingg U, McQuinn A, DiValentino D, Esterman AJ, Bessell JR, Thompson SK, et al. Minimally invasive versus open esophagectomy for patients with esophageal cancer. Ann Thorac Surg. 2009;87(3):911–9.

40. Luketich JD, Pennathur A, Franchetti Y, Calzadilla P, Swanson S, Sugarbaker DJ, et al. Minimally invasive esophagectomy: results of a prospective phase II multicenter trial. Asian cooperative oncology group (E2202) study. Ann Surg. 2015;261(4):702–7.

41. Conroy MA, Dolan JP, Latour E, Lim JY, Siegal S, Schipper PH, et al. Readmission patterns at 30 and 90 days after esophagectomy: a single NCI-designated cancer center experience. J Am Coll Surg. 2017;225(4):e94.

42. Sakamoto T, Fujisuga M, Matsui H, Fushimi K, Yasunaga H. Comparing perioperative mortality and morbidity of minimally invasive esophagectomy versus open esophagectomy for esophageal cancer: a nationwide retrospective analysis. Ann Surg. 2019;274:324–30.

43. Naftuep X, Moons J, Coosemans W, Decaluwe H, Decker G, De Leyen P, et al. Minimally invasive esophagectomy: a valuable alternative to open esophagectomy for the treatment of early oesophageal and gastro-oesophageal junction carcinoma. Eur J Cardio-Thorac Surg. 2017;50(5):876–80.

44. Osugi H, Takamura M, Higashino M, Takada N, Lee S, Kinoshita H. A comparison of video-assisted thorascopic oesophagectomy and radical lymph node dissection for squamous cell cancer of the oesophagus with open operation. Br J Surg. 2003;90(1):108–13.

45. Takeno S, Takahashi Y, Moroga T, Kawahara K, Yamashita Y, Ohtaki M. Retrospective study using the propensity score to clarify the oncologic feasibility of thorascoscopic esophagectomy in patients with esophageal cancer. World J Surg. 2013;37(7):1673–80.

46. Ybulyavin W, Abulzi S, Lv H, Sun W. Minimally invasive oesophagectomy versus open esophagectomy for resectable esophageal cancer: a meta-analysis. World J Surg. 2016;41(1):304.

47. Kidane B, Kaaki S, Hirpara DH, Shen YC, Basilli A, Allison F, et al. Emergency department use is high after esophagectomy and feeding tube problems are the biggest culprit. J Thorac Cardiovasc Surg. 2018;156(6):2340–8.

48. Gordon NP. Similarity of adult Kaiser Permanente Members to the adult populations in an integrated health care delivery system. JAMA Surg. 2020;156(2):170–4.

49. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, committee E. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):499–55.
55. Saltzman JR, Gibson MK. Clinical manifestations, diagnosis, and staging of esophageal cancer. In: UpToDate. Waltham, MA: UpToDate; 2020 [cited 2020 Nov 24]. https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-staging-of-esophageal-cancer
56. Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP. [cited 2020 Jan 4]. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
57. Surveillance, Epidemiology, and End Results Program. SEER. [cited 2018 Dec 21]. https://seer.cancer.gov/index.html.
58. Clopper C, Pearson E. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26(4):404–13.
59. Kleinbaum DG, Klein M. Survival analysis, vol. 2. Springer; 2005.
60. Zhang J, Wang R, Liu S, Luketic JD, Chen S, Chen H, et al. Refinement of minimally invasive esophagectomy techniques after 15 years of experience. J Gastrointest Surg. 2012;16(9):1768–74.
61. Lee J-M, Cheng J-W, Lin M-T, Huang P-M, Chen J-S, Lee Y-C. Is there any benefit to incorporating a laparoscopic procedure into minimally invasive esophagectomy? The impact on perioperative results in patients with esophageal cancer. World J Surg. 2011;35(4):790–7.
62. Hamouda AH, Forshaw MJ, Tsigritis K, Jones GE, Noorani AS, Rohatgi A, et al. Perioperative outcomes after transition from conventional to minimally invasive Ivor-Lewis esophagectomy in a specialized center. Surg Endosc. 2010;24(4):865–9.
63. Schröder W, Hölscher AH, Bludau M, Vallbohmer D, Bollschweiler E, Gutschow C. Ivor-Lewis esophagectomy with and without laparoscopic conditioning of the gastric conduit. World J Surg. 2010;34(4):738–43.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.